4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$8.53 USD
+0.08 (0.95%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $8.53 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
FDMT 8.53 +0.08(0.95%)
Will FDMT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for FDMT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FDMT
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
FDMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think 4D Molecular Therapeutics (FDMT) Could Surge 225.1%: Read This Before Placing a Bet
4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates
Other News for FDMT
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure
4D Molecular Therapeutics downgraded at Cantor following wet AMD asset data
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2024 Commentary
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
Janus Henderson Global Life Sciences Fund Q2 2024 Commentary